Research conducted at QIMR Berghofer has been commercialised into a product, to be launched in Brisbane this week, that better detects one of the most dangerous cancers.
The World Congress for Esophageal Diseases, being held at the Brisbane Convention and Exhibition Centre until Saturday, will see a new blood test revealed for Esophageal cancer (EAC).
Proteomics International Managing Director Dr Richard Lipscombe said the PromarkerEso was a world-first protein biomarker-based blood diagnostic that could rule out EAC, “one of the deadliest forms of cancer”.
